Anti-diabetic drug metformin: Challenges and perspectives for cancer therapy

Current Cancer Drug Targets

Volumn 14, Issue 8, 2014, Pages 727-736

  Snima, Kaniyampadi Sreenivasan ^a   Pillai, Prathesha ^a   Cherian, Aleena Mary ^a   Nair, Shantikumar V ^a   Lakshmanan, Vinoth Kumar ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Breast cancer; Endometrial cancer; Metformin; Nanotechnology; Ovarian cancer; Pancreatic cancer; Pathways; Prostate cancer

Indexed keywords

ADENYLATE KINASE; EUDRAGIT; METFORMIN; MICRORNA; NANOPARTICLE; PROTEIN BCL 2; PROTEIN KINASE LKB1; PROTEIN P53; SOMATOMEDIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RISK; CANCER STEM CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOTOXICITY; DRUG ABSORPTION; DRUG MECHANISM; ENDOCYTOSIS; INSULIN BLOOD LEVEL; NANOTECHNOLOGY; NEOPLASM; OVERALL SURVIVAL; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HUMAN; NEOPLASMS; RETROSPECTIVE STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

EID: 84919727164     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666141020105502     Document Type: Article

References (114)

1. El-Serag, H.B.; Hampel, H.; Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol., 2006, 4, 369-380.
2. Lipscombe, L.L.; Hux, J.E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet, 2007, 369, 750-756.
3. Witters, L.A. The blooming of the French lilac. J. Clin. Invest., 2001, 108(8), 1105-1107.
4. Turner, R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-865.
5. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108, 1167-1174.
6. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Cufí, S.; Martin-Castillo, B.; Menendez, J.A. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr. Mol. Med., 2010, 10, 674-691.
7. Medical News Today. "Tried and True"Diabetes Drug Still the Best after 15 Years. www.medicalnewstoday.com/articles/21900.php.
8. Goodwin, P.J.; Pritchard, K.I.; Ennis, M.; Clemons, M.; Graham, M.; Fantus, I.G. Insulin-lowering effects of metformin in women with early breast cancer. Breast Cancer Res. Treat., 2001, 126, 215-220.
9. Ben Sahra, I.; Laurent, K.; Loubat, A. Giorgetti-Peraldi, S.; Colosetti, P.; Auberge, R P.; Tanti, J.F.; Le Marchand-Brustel, Y.; Bost, F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008, 27, 3576-3586.
10. Stephenne, X.; Foretz, M.; Taleux, N. van der Zon, G.C.; Sokal, E.; Hue, L.; Viollet, B.; Guigas, B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia, 2011, 54, 3101-3110.
11. Giovannucci, E.; Harlan, D.M.; Archer, M.C. Bergenstal, R.M.; Gapstur, S.M.; Habel, L.A.; Pollak, M.; Regensteiner, J.G.; Yee, D. Diabetes and cancer: a consensus report. Diabetes Care, 2010, 33, 1674-1685.
12. Rizos, C.V.; Elisaf, M.S.; Metformin and cancer. Eur. J. Pharmacol., 2013, 705, 96-108.
13. Lipscombe, L.L.; Goodwin, P.J.; Zinman, B.; McLaughlin, J.R.; Hux, J.E. The impact of diabetes on survival following breast cancer. Breast Cancer Res. Treat., 2008, 109, 389-395.
14. Meyerhardt, J.A.; Catalano, P.J.; Haller, D.G. Mayer, R.J.; Macdonald, J.S.; Benson, A.B.; Fuchs, C.S. Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol., 2003, 21, 433-440.
15. Hosono, K.; Endo, H.; Takahashi, H. et al.Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila)., 2010, 3, 1077-1083.
16. Zakikhani, M.; Blouin, M.J.; Piura, E.; Pollak, M.N. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res. Treat., 2010, 123, 271-279.
17. Cantrell, L.A.; Zhou, C.; Mendivil, A.; Malloy, K.M.; Gehrig, P.A.; Bae-Jump, V.L. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol. Oncol., 2010, 116, 92-98.
18. Zhuang, Y.; Miskimins, W.K. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J. Mol. Signal., 2008, 3, 18.
19. Del Barco, S.; Vazquez-Martin, A.; Cufí, S.; Oliveras-Ferraros, C.; Bosch-Barrera, J.; Joven, J.; Martin-Castillo, B.; Menendez, J.A. Metformin: multi-faceted protection against cancer. Oncotarget, 2011, 2, 896-917.
20. Belda-Iniesta, C.; Pernia, O.; Simo, R. Metformin: A new option in cancer treatment. Clin. Transl. Oncol., 2011, 13, 363-367.
21. Janjetovic, K.; Harhaji-Trajkovic, L.; Misirkic-Marjanovic, M.; Vucicevic, L.; Stevanovic, D.; Zogovic, N.; Sumarac-Dumanovic, M.; Micic, D.; Trajkovic, V. In vitro and in vivo anti-melanoma action of metformin. Eur. J. Pharmacol., 2011, 668, 373-382.
22. Cerezo, M.; Tichet, M.; Abbe, P.; Ohanna, M.; Lehraiki, A.; Rouaud, F.; Allegra, M.; Giacchero, D.; Bahadoran, P.; Bertolotto, C.; Tartare-Deckert, S.; Ballotti, R.; Rocchi, S. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol. Cancer Ther., 2013, 12, 1605-1615.
23. Tomic, T.; Botton, T.; Cerezo, M.; Robert, G.; Luciano, F.; Puissant, A.; Gounon, P.; Allegra, M.; Bertolotto, C.; Bereder, J.M.; Tartare-Deckert, S.; Bahadoran, P.; Auberger, P.; Ballotti, R.; Rocchi, S. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis., 2011, 2, e199.
24. Jiralerspong, S.; Palla, S.L.; Giordano, S.H.; Meric-Bernstam, F.; Liedtke, C.; Barnett, C.M.; Hsu, L.; Hung, M.C.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol., 2009, 27, 3297-3302.
25. He, X.L.; Esteva, F.J.; Ensor, J.; Hortobagyi, G.N.; Lee, M.H.; Yeung, S.C. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann. Oncol., 2012, 23, 1771-1780.
26. Qu, C.; Zhang, W.; Zheng, G.; Zhang, Z.; Yin, J.; He, Z. Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol. Cell Biochem., 2014, 386, 63-71.
27. Koh, M.; Lee, J.C.; Min, C.; Moon, A. A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells. Bioorg. Med. Chem., 2013, 21, 2305-2313.
28. Chlebowski, R.T.; McTiernan, A.; Wactawski-Wende, J.; Wactawski-Wende, J.; Manson, J.E.; Aragaki, A.K.; Rohan, T.; Ipp, E.; Kaklamani, V.G.; Vitolins, M.; Wallace, R.; Gunter, M.; Phillips, L.S.; Strickler, H.; Margolis, K.; Euhus, D.M. Diabetes, metformin, and breast cancer in postmenopausal women. J. Clin. Oncol., 2012, 30, 2844-2852.
29. Zheng, Y.W.; Li, R.M.; Zhang, X.W.; Ren, X.B. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest., 2013, 31, 197-205.
30. Wang, Y.; Dai, W.; Chu, X.; Yang, B.; Zhao, M.; Sun, Y. Metformin inhibits lung cancer cells proliferation through repressing microRNA-222. Biotechnol. Lett., 2013, 35, 2013-2019.
31. Salani, B.; Maffioli, S.; Hamoudane, M.; Parodi, A.; Ravera, S.; Passalacqua, M.; Alama, A.; Nhiri, M.; Cordera, R.; Maggi, D. Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J., 2012, 26, 788-798.
32. Mazzone, P.; Rai, H.; Beukemann, M.; Xu, M.; Jain, A.; Sasidhar, M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer, 2012, 12, 410.
33. Nicotra, G.; Mercalli, F.; Peracchio, C.; Castino, R.; Follo, C.; Valente, G.; Isidoro, C. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod. Pathol., 2010, 23, 937-950
34. Viana, R.; Aguado, C.; Esteban, I.; Moreno, D.; Viollet, B.; Knecht, E.; Sanz, P. Role of AMP-activated protein kinase in autophagy and proteasome function. Biochem. Biophys. Res. Commun., 2008, 369, 964-968.
35. Shi, WY.; Xiao, D.; Wang, L.; Dong, L.H.; Yan, Z.X.; Shen, Z.X.; Chen, S.J.; Chen, Y.; Zhao, W.L. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis., 2012, 3, e275.
36. Sadeghi, N.; Abbruzzese, J.L.; Yeung, S.C.J.; Hassan, M.; Li, D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin. Cancer Res., 2012, 18, 2905-2912.
37. SinnettSmith, J.; Kisfalvi, K.; Kui, R.; Rozengurt, E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem. Biophys. Res. Commun., 2013, 430, 352-357.
38. Li, W.; Yuan, Y.; Huang, L.; Qiao, M.; Zhang, Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res. Clin. Pract.,2012, 96, 187-195.
39. Karnevi, E.; Said, K.; Andersson, R.; Rosendahl, A.H. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer, 2013, 13, 235.
40. Bao, B.; Wang, Z.; Ali, S.; Ahmad, A.; Azmi, A.S.; Sarkar, S.H.; Banerjee, S.; Kong, D.; Li, Y.; Thakur, S.; Sarkar, F.H. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila)., 2012, 5, 355-364.
41. Nair, V.; Pathi, S.; Jutooru.; Sreevalsan, S.; Basha, R.; Abdelrahim, M.; Samudio, I.; Safe, S. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis, 2013, 34, 2870-2879.
42. Rozengurt.; Sinnet-Smith.; Kisfalvi, K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res., 2010, 16, 2505-2511.
43. Gou.; Cui.; Li.; Shi.; Liu.; Wang, C. Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One, 2013, 8, e63969.
44. Lonardo.; Cioffi.; Sancho. Sanchez-Ripoll, Y.; Trabulo, S.M.; Dorado, J.; Balic, A.; Hidalgo, M.; Heeschen, C. Metformin Targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One, 2013, 8.
45. Mohammed; Janakiram, N.; Brewer. Ritchie, R.L.; Marya, A.; Lightfoot, S.; Steele, V.E.; Rao, C.V. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl. Oncol., 2013, 6, 649-659.
46. El-Serag, H.; Rudolph, K.L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132, 2557-2576.
47. Donadon, V.; Balbi.; Mas, M.; Casarin.; Zanette, G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int.,2010, 30, 750-758.
48. Donadon, V.; Balbi. M.; Ghersetti, M.; Grazioli, S.; Perciaccante, A.; Della Valentina, G.; Gardenal, R.; Dal Mas, M.; Casarin. P.; Zanette, G.; Miranda, C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol.,2009, 15, 2506-2511.
49. Chen, T.; Lin, C.; Huang, P.T.; Wen, C.F. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J. Gastroenterol. Hepatol., 2011, 26, 858-865.
50. Bhalla, K.; Hwang, B.J.; Dewi, R.E.; Twaddel, W.; Goloubeva, O.G.; Wong, K.K.; Saxena, N.K.; Biswal, S.; Girnun, G.D. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev. Res. (Phila)., 2012, 5, 544-552.
51. Lee, J.H.; Kim, T.; Jeon, S.M.; Hong, S.P.; Cheon, J.H.; Kim, W.H. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int. J. Cancer, 2012, 131, 752-759.
52. Zhang, Z.; Zheng, Z.; Kan.; Song, Y.; Cui, W.; Zhao, G.; Kip, K.E. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care, 2011, 34, 2323-2328.
53. Zhou, X.; Xue, Y.; Zhu, B.; Sha, J. [Effects of metformin on proliferation of human colon carcinoma cell line SW-480]. Nan Fang Yi Ke Da Xue Xue Bao2010, 30, 1935, 1938, 1942.
54. Zhang, Y.; Guan, M.; Zheng, Z.; Zhang, Q.; Gao, F.; Xue, Y. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One, 2013, 8, e81264.
55. Currie, C.J.; Poole, C.D.; Gale, E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 2009, 52, 1766-1777.
56. Wright, J.L.; Stanford, J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control., 2009, 20, 1617-1622.
57. Kaushik, D.; Karnes, R.J.; Eisenberg, M.S.; Rangel, L.J.; Carlson, R.E.; Bergstralh, E.J. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol. Oncol., 2014, 32, 1-7.
58. Margel, D.; Urbach, D.; Lipscombe, L.L.; Bell, C.M.; Kulkarni, G.; Austin, P.C.; Fleshner, N. Association between metformin use and risk of prostate cancer and its grade. J. Natl. Cancer Inst., 2013, 105, 1123-1131.
59. Spratt, D.E.; Zhang, C.; Zumsteg, Z.S.; Pei, X.; Zhang, Z.; Zelefsky, M.J. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur. Urol., 2013, 63, 709-716.
60. Avci, C.B.; Harman, E.; Dodurga, Y.; Susluer, S.Y.; Gunduz, C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac. J. Cancer Prev., 2013, 14, 765-768.
61. Suri, A.; Schuler, K.; Zhou, C.; Malloy, K.; Dickens, H.; Steplowski, T.; Huh, G.; Gehrig, P.; Bae-Jump, V. Metformin potently inhibits cell proliferation, adhesion and invasion in ovarian cancer cells. Gynecol. Oncol., 2012, 125, S189-S190.
62. Yasmeen, A.; Beauchamp, M.C.; Piura, E.; Segal, E.; Pollak, M.; Gotlieb, W.H. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol. Oncol., 2011, 121, 492-498.
63. Bodmer, M.; Becker, C.; Meier, C.; Jick, S.S.; Meier, C.R. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol. Oncol., 2011, 123, 200-204.
64. Kumar, S.; Meuter, A.; Thapa, P.; Langstraat, C.; Giri, S.; Chien, J.; Rattan, Cliby, W.; Shridhar, V. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer, 2013, 119, 555-62.
65. Shank, J.J.; Yang, K.; Ghannam, J.; Cabrera, L.; Johnston, C.J.; Reynolds, R.K.; Buckanovich, R.J. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol., 2012, 127, 390-397.
66. Chan, D.K.; Miskimins, W. Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures. J. Ovarian Res., 2012, 5, 19.
67. Zhang, Q.; Celestino, J.; Schmandt, R.; McCampbell, A.S.; Urbauer, D.L.; Meyer, L.A.; Burzawa, J.K.; Huang, M.; Yates, M.S.; Iglesias, D.; Broaddus, R.R.; Lu, K.H. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am. J. Obstet. Gynecol., 2013, 209, 24. e1-24.e12.
68. Xie, Y.; Wang, Y.L.; Yu, L.; Hu, Q.; Ji, L.; Zhang, Y.; Liao, Q.P. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J. Steroid Biochem. Mol. Biol., 2011, 126, 113-120.
69. Hanna, R.K.; Zhou, C.; Malloy, K.M.; Sun, L.; Zhong, Y.; Gehrig, P.A.; Bae-Jump, V.L. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol. Oncol., 2012, 125, 458-469.
70. Nevadunsky, N.S.; Van Arsdale, A.; Strickler, H.D.; Moadel, A.; Kaur, G.; Frimer, M.; Conroy, E.; Goldberg, G.L.; Einstein, M.H. Metformin use and endometrial cancer survival. Gynecol. Oncol., 2014, 132, 236-240.
71. Sarfstein, R.; Friedman, Y.; Attias-Geva, Z.; Fishman, A.; Bruchim, I.; Werner, H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One2013, 8, e61537.
72. Xiao, X.; He, Q.; Lu, C.; Werle, K.D.; Zhao, R.X.; Chen, J.; Davis, B.C.; Cui, R.; Liang, J.; Xu, Z.X. Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol. Oncol., 2012, 127, 249-255.
73. Evans, J.M.M.; Donnelly, L.A.; Emslie-Smith, A.M.; Alessi, D.R.; Morris, A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ Br. Med. J., 2005, 330, 1304-1305.
74. Martin-Montalvo, A.; Mercken, E.M.; Mitchell, S.J.; Palacios, H.H.; Mote, P. Metformin improves healthspan and lifespan in mice. Nat. Commun., 2013, 4, 2192.
75. Ouyang, J.; Parakhia, R.A.; Ochs, R.S. Metformin activates AMP kinase through inhibition of AMP deaminase. J. Biol. Chem., 2011, 286, 1-11.
76. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J., 2000, 348, 607-614.
77. El-Mir, M.Y.; Nogueira, V.; Fontaine, E.; Avéret, N.; Rigoulet, M.; Leverve, X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem., 2000, 275, 223-228.
78. Ota, S.; Horigome, K.; Ishii, T.; Nakai, M.; Hayashi, K.; Kawamura, T.; Kishino, A.; Taiji, M.; Kimura, T. Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism. Biochem. Biophys. Res. Commun., 2009, 388, 311-316.
79. Shaw, R.J.; Lamia, K.A.; Vasquez, D.; Koo, S.H.; Bardeesy, N.; Depinho, R.A.; Montminy, M.; Cantley, L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005, 310, 1642-1646.
80. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad Sci., 2004, 101, 3329-3335.
81. Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell, 2003, 115, 577-590.
82. Gwinn, D.M.; Shackelford, D.B.; Egan, D.F.; Mihaylova, M.M.; Mery, A.; Vasquez, D.S.; Turk, B.E.; Shaw, R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol. Cell, 2008, 30, 214-226.
83. Thoreen, C.C.; Sabatini, D.M. AMPK and p53 help cells through lean times. Cell Metab., 2005, 1, 287-288.
84. Buzzai, M.; Jones, R.G.; Amaravadi, R.K.; Lum, J.J.; DeBerardinis, R.J.; Zhao, F.; Viollet, B.; Thompson, C.B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res., 2007, 67, 6745-6752.
85. Kisfalvi, K.; Eibl, G.; Sinnett-Smith, J.; Rozengurt, E. Metformin Disrupts crosstalk between G protein-coupled receptorand insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res., 2009, 69, 6539-6545.
86. Foretz, M.; Hébrard, S.; Leclerc, J.; Zarrinpashneh, E.; Soty, M.; Mithieux, G.; Sakamoto, K.; Andreelli, F.; Viollet, B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest., 2010, 120, 2355-2369.
87. Ben Sahra, I.; Regazzetti, C.; Robert, G.; Laurent, K.; Le Marchand-Brustel, Y.; Auberger, P.; Tanti, J.F.; Giorgetti-Peraldi, S.; Bost, F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res., 2011, 71, 4366-4372.
88. Kalender, A.; Selvaraj, A.; Kim, SY.; Gulati, P.; Brûlé, S.; Viollet, B.; Kemp, B.E.; Bardeesy, N.; Dennis, P.; Schlager, J.J.; Marette, A.; Kozma, S.C.; Thomas, G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab., 2010, 11, 390-401.
89. Sancak, Y.; Peterson, T.R.; Shaul, Y.D.; Lindquist, R.A.; Thoreen, C.C.; Bar-Peled, L.; Sabatini, D.M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science, 2008, 320, 1496-1501.
90. Mega, S.; Miyamoto, M.; Ebihara, Y.; Takahashi, R.; Hase, R.; Li, L.; Shichinohe, T.; Kawarada, Y.; Uehara, H.; Kaneko, H.; Hashimoto, H.; Murakami, Y.; Itoh, T.; Morikawa, T.; Kondo, S. Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis. Esophagus, 2005, 18, 109-113.
91. Alimova, I.N.; Liu. B.; Fan, Z.; Edgerton, S.M.; Dillon, T.; Lind, S.E.; Thor, A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 2009, 8, 909-915.
92. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Menendez, J.A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 2009, 8, 88-96.
93. Hirsch, H.A.; Iliopoulos, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res., 2009, 69, 7507-7511.
94. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Cufí, S.; DelBarco, S.; Martin-Castillo, B.; Menendez, J.A. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle, 2010, 15(9), 3807-3814.
95. Vazquez-Martin, A.; Oliveras-Ferraros, C.; Cufí, S.; Del Barco, S.; Martin-Castillo, B.; Lopez-Bonet, E.; Menendez, J.A. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol. Rep., 2011, 25, 135-140.
96. Tan, B.K.; Adya, R.; Chen, J.; Lehnert, H.; Sant Cassia, L.J.; Randeva, H.S. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J. Clin. Endocrinol. Metab., 2011, 96, 808-816.
97. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update.Nat. Rev. Cancer, 2012, 12, 159-69.
98. Algire, C.; Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.; Pollak, M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene, 2011, 30, 1174-1182.
99. Pawelczyk, L., Spaczynski, R.Z.; Banaszewska, B.; Duleba, A.J. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod Biol., 2004, 113, 209-213.
100. Algire, C.; Moiseeva, O.; Deschenes-Simard, X.; Amrein, L.; Petruccelli, Birman, E.; Viollet, B.; Ferbeyre, G.; Pollak, M.N. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cac. Prev. Res. (Phila)., 2012, 5, 536-543.
101. Gusler, G.; Gorsline, J.; Levy, G.; Zhang, S.; Weston, I.E.; Naret, D.; Berner, B. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers. J. Clin. Pharmacol., 2001, 41(6), 655-661.
102. Scheen, A.J. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 1996, 30, 359-371.
103. Graham, G.G.; Punt, J.; Arora, M.; Day, R.; Doogue, M.P.; Duong, J.K.; Furlong, T.J.; Greenfield, J.R.; Greenup, L.C.; Kirkpatrick, C.M.; Ray, J.E.; Timmins, P.; Williams, K.M.. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 2011, 50, 81-98.
104. Robert, F.; Fendri, S.; Hary, L.; Lacroix, C.; Andréjak, M.; Lalau, J.D. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab., 2003, 29, 279-283.
105. Roussel, R.; Travert, F.; Pasquet, B.; Wilson, P.W.; Smith, S.C.; Goto, S.; Ravaud, P.; Marre, M.; Porath, A.; Bhatt, D.L.; Steg, P.G. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med., 2010, 170, 1892-1899.
106. Christiansen, C.F.F.; Johansen, M.B.B.; Christensen, S. O.; Brien, J.M.; Tønnesen, E.; Sørensen, H.T.T. Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study. Crit. Care, 2013, 17, R192.
107. Nasa, P.; Mahant, S.; Sharma, D. Floating systems: a novel approach towards gastroretentive drug delivery systems. Int. J. Pharm. Pharm. Sci. 2010, 2, 1-7.
108. Holguín, G.; Cuesta, F.; Archbold, R.; Restrepo, M.; Parra, S.; Lina Peña, Montoya, B.; Ríos, J.C.; Ruiz, A. Bioavalaibility and pharmacokinetic comparison of two formulations of metformin 850 mg tablets in healthy Colombian volunteers. Comp.la biodisponibilidad y la Farm. entre dos formulaciones tabletas metformina 850 mg en Volunt. Colomb. sanos, 2011, 42, 81-87.
109. Cetin, M.; Atila, A.; Sahin, S.; Vural, I. Preparation and characterization of metformin hydrochloride loaded- Eudragit®RSPO and Eudragit®RSPO/PLGA nanoparticles. Pharm. Dev. Technol., 2013, 18, 570-6.
110. Sharma, N.; Rana, S.; Hosakote, G.; Shivkumar.; Sharma, R.K. Solid lipid nanoparticles as a carrier of metformin for transdermal delivery. Int. J. Drug Delivery, 2013, 5, 137-145.
111. Lekshmi, U.M.; Reddy, P.N. Preliminary toxicological report of metformin hydrochloride loaded polymeric nanoparticles. Toxicol. Int., 2012, 19, 267-272.
112. Snima, K.S.; Jayakumar, R.; Unnikrishnan, A. G.; Nair, S. V.; Lakshmanan, V.K. O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. Carbohydr. Polym., 2012, 89, 1003-1007.
113. Snima, K.S.; Jayakumar, R.; Lakshmanan, V.K. In vitro and In vivo biological evalution of metformin encapuslated OCMC nanopartciles for pancreatic cancer therapy. J. Pharma. Res., 2014, (In press).
114. Snima, K.S.; Reshmi, S.N.; Nair, S.V.; Ravindranath, K.C.; Lakshmanan, V.K. Combination of anti-diabetic drug metformin and boswellic acid nanoparticles: A novel strategy for pancreatic cancer therapy. J. Biomed. Nanotechnol., 2014, 10, 1-12.